{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,3]],"date-time":"2026-07-03T19:01:37Z","timestamp":1783105297396,"version":"3.54.6"},"reference-count":47,"publisher":"Portland Press Ltd.","issue":"7","license":[{"start":{"date-parts":[[2020,3,13]],"date-time":"2020-03-13T00:00:00Z","timestamp":1584057600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/2.0\/"}],"content-domain":{"domain":["portlandpress.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2020,4,17]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>The clinical effectiveness of adrenocorticotropin in inducing remission of steroid-resistant nephrotic syndrome points to a steroidogenic-independent anti-proteinuric activity of melanocortins. However, which melanocortin receptors (MCR) convey this beneficial effect and if systemic or podocyte-specific mechanisms are involved remain uncertain. In vivo, wild-type (WT) mice developed heavy proteinuria and kidney dysfunction following Adriamycin insult, concomitant with focal segmental glomerulosclerosis (FSGS) and podocytopathy, marked by loss of podocin and synaptopodin, podocytopenia and extensive foot process effacement on electron microscopy. All these pathologic findings were prominently attenuated by NDP-MSH, a potent non-steroidogenic pan-MCR agonist. Surprisingly, MC1R deficiency in MC1R-null mice barely affected the severity of Adriamycin-elicited injury. Moreover, the beneficial effect of NDP-MSH was completely preserved in MC1R-null mice, suggesting that MC1R is likely non-essential for the protective action. A direct podocyte effect seems to contribute to the beneficial effect of NDP-MSH, because Adriamycin-inflicted cytopathic signs in primary podocytes prepared from WT mice were all mitigated by NDP-MSH, including apoptosis, loss of podocyte markers, de novo expression of the podocyte injury marker desmin, actin cytoskeleton derangement and podocyte hypermotility. Consistent with in vivo findings, the podoprotective activity of NDP-MSH was fully preserved in MC1R-null podocytes. Mechanistically, MC1R expression was predominantly distributed to glomerular endothelial cells in glomeruli but negligibly noted in podocytes in vivo and in vitro, suggesting that MC1R signaling is unlikely involved in direct podocyte protection. Ergo, melanocortin therapy protects against podocyte injury and ameliorates proteinuria and glomerulopathy in experimental FSGS, at least in part, via a podocyte-specific non-MC1R-mediated melanocortinergic signaling.<\/jats:p>","DOI":"10.1042\/cs20200016","type":"journal-article","created":{"date-parts":[[2020,3,13]],"date-time":"2020-03-13T11:40:25Z","timestamp":1584099625000},"page":"695-710","update-policy":"https:\/\/doi.org\/10.1042\/crossmark_policy","source":"Crossref","is-referenced-by-count":18,"title":["Melanocortin therapy ameliorates podocytopathy and proteinuria in experimental focal segmental glomerulosclerosis involving a podocyte specific non-MC1R-mediated melanocortinergic signaling"],"prefix":"10.1042","volume":"134","author":[{"given":"Yingjin","family":"Qiao","sequence":"first","affiliation":[{"name":"Division of Kidney Disease and Hypertension, Department of Medicine, Rhode Island Hospital, Brown University School of Medicine, Providence, Rhode Island, U.S.A."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pei","family":"Wang","sequence":"additional","affiliation":[{"name":"Division of Kidney Disease and Hypertension, Department of Medicine, Rhode Island Hospital, Brown University School of Medicine, Providence, Rhode Island, U.S.A."},{"name":"Institute of Nephrology, Blood Purification Center, the First Affiliated Hospital of Zhengzhou University, Zhengzhou, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mingyang","family":"Chang","sequence":"additional","affiliation":[{"name":"Division of Nephrology, University of Toledo College of Medicine, Toledo, Ohio, U.S.A."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bohan","family":"Chen","sequence":"additional","affiliation":[{"name":"Division of Kidney Disease and Hypertension, Department of Medicine, Rhode Island Hospital, Brown University School of Medicine, Providence, Rhode Island, U.S.A."},{"name":"Division of Nephrology, University of Toledo College of Medicine, Toledo, Ohio, U.S.A."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan","family":"Ge","sequence":"additional","affiliation":[{"name":"Division of Kidney Disease and Hypertension, Department of Medicine, Rhode Island Hospital, Brown University School of Medicine, Providence, Rhode Island, U.S.A."},{"name":"Division of Nephrology, University of Toledo College of Medicine, Toledo, Ohio, U.S.A."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deepak\u00a0K.","family":"Malhotra","sequence":"additional","affiliation":[{"name":"Division of Nephrology, University of Toledo College of Medicine, Toledo, Ohio, U.S.A."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lance\u00a0D.","family":"Dworkin","sequence":"additional","affiliation":[{"name":"Division of Kidney Disease and Hypertension, Department of Medicine, Rhode Island Hospital, Brown University School of Medicine, Providence, Rhode Island, U.S.A."},{"name":"Division of Nephrology, University of Toledo College of Medicine, Toledo, Ohio, U.S.A."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6302-2800","authenticated-orcid":false,"given":"Rujun","family":"Gong","sequence":"additional","affiliation":[{"name":"Division of Kidney Disease and Hypertension, Department of Medicine, Rhode Island Hospital, Brown University School of Medicine, Providence, Rhode Island, U.S.A."},{"name":"Division of Nephrology, University of Toledo College of Medicine, Toledo, Ohio, U.S.A."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"288","published-online":{"date-parts":[[2020,3,30]]},"reference":[{"key":"2021113011105255000_B1","doi-asserted-by":"publisher","first-page":"502","DOI":"10.2215\/CJN.05960616","article-title":"Focal Segmental Glomerulosclerosis","volume":"12","author":"Rosenberg","year":"2017","journal-title":"Clin. J. Am. Soc. Nephrol.: CJASN"},{"key":"2021113011105255000_B2","doi-asserted-by":"publisher","first-page":"2398","DOI":"10.1056\/NEJMra1106556","article-title":"Focal segmental glomerulosclerosis","volume":"365","author":"D'Agati","year":"2011","journal-title":"N. Engl. J. Med."},{"key":"2021113011105255000_B3","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1053\/j.ackd.2014.05.010","article-title":"Permeability factors in focal and segmental glomerulosclerosis","volume":"21","author":"Reiser","year":"2014","journal-title":"Adv. Chronic Kidney Dis."},{"key":"2021113011105255000_B4","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1007\/s00467-006-0370-5","article-title":"Focal segmental glomerulosclerosis\u2013epidemiology aspects in children and adults","volume":"22","author":"Hogg","year":"2007","journal-title":"Pediatric Nephrol. (Berlin, Germany)."},{"key":"2021113011105255000_B5","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1038\/nrneph.2014.216","article-title":"Causes and pathogenesis of focal segmental glomerulosclerosis","volume":"11","author":"Fogo","year":"2015","journal-title":"Nat. Rev. Nephrol."},{"key":"2021113011105255000_B6","doi-asserted-by":"publisher","first-page":"408","DOI":"10.1053\/j.ackd.2014.05.009","article-title":"The pathogenesis of focal segmental glomerulosclerosis","volume":"21","author":"Jefferson","year":"2014","journal-title":"Adv. Chronic Kidney Dis."},{"key":"2021113011105255000_B7","doi-asserted-by":"publisher","first-page":"1769","DOI":"10.1681\/ASN.2012040389","article-title":"Treatment of primary FSGS in adults","volume":"23","author":"Korbet","year":"2012","journal-title":"J. Am. Soc. Nephrol."},{"key":"2021113011105255000_B8","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1053\/j.ackd.2013.09.004","article-title":"Leveraging melanocortin pathways to treat glomerular diseases","volume":"21","author":"Gong","year":"2014","journal-title":"Adv. Chronic Kidney Dis."},{"key":"2021113011105255000_B9","doi-asserted-by":"publisher","first-page":"E468","DOI":"10.1152\/ajpendo.00434.2002","article-title":"The melanocortin system","volume":"284","author":"Gantz","year":"2003","journal-title":"Am. J. Physiol. Endocrinol. Metab."},{"key":"2021113011105255000_B10","doi-asserted-by":"publisher","first-page":"736","DOI":"10.1210\/er.2006-0034","article-title":"Studies on the physiological functions of the melanocortin system","volume":"27","author":"Cone","year":"2006","journal-title":"Endocr. Rev."},{"key":"2021113011105255000_B11","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1111\/j.1749-6632.1999.tb08662.x","article-title":"The proopiomelanocortin system","volume":"885","author":"Hadley","year":"1999","journal-title":"Ann. N. Y. Acad. Sci."},{"key":"2021113011105255000_B12","first-page":"287","article-title":"The melanocortin receptors: agonists, antagonists, and the hormonal control of pigmentation","volume":"51","author":"Cone","year":"1996","journal-title":"Recent Prog. Horm. Res."},{"key":"2021113011105255000_B13","doi-asserted-by":"publisher","first-page":"434","DOI":"10.1007\/PL00000868","article-title":"Melanocortin receptors: their functions and regulation by physiological agonists and antagonists","volume":"58","author":"Abdel-Malek","year":"2001","journal-title":"Cell. Mol. Life Sci.: CMLS"},{"key":"2021113011105255000_B14","doi-asserted-by":"publisher","first-page":"372","DOI":"10.1136\/adc.28.141.372","article-title":"A.C.T.H. in nephrosis","volume":"28","author":"Arneil","year":"1953","journal-title":"Arch. Dis. Childhood."},{"key":"2021113011105255000_B15","first-page":"152","article-title":"Management of nephrosis; the use of long continued hormone therapy","volume":"85","author":"Piel","year":"1956","journal-title":"Calif. Med."},{"key":"2021113011105255000_B16","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1038\/nrneph.2011.190","article-title":"The renaissance of corticotropin therapy in proteinuric nephropathies","volume":"8","author":"Gong","year":"2011","journal-title":"Nat. Rev. Nephrol."},{"key":"2021113011105255000_B17","doi-asserted-by":"publisher","first-page":"1305","DOI":"10.1093\/ndt\/gfh110","article-title":"ACTH-induced improvement in the nephrotic syndrome in patients with a variety of diagnoses","volume":"19","author":"Berg","year":"2004","journal-title":"Nephrol. Dial. Transplant."},{"key":"2021113011105255000_B18","doi-asserted-by":"publisher","first-page":"147","DOI":"10.2147\/DDDT.S17521","article-title":"Treatment of nephrotic syndrome with adrenocorticotropic hormone (ACTH) gel","volume":"5","author":"Bomback","year":"2011","journal-title":"Drug Design Dev. Ther."},{"key":"2021113011105255000_B19","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1159\/000339287","article-title":"Treatment of resistant glomerular diseases with adrenocorticotropic hormone gel: a prospective trial","volume":"36","author":"Bomback","year":"2012","journal-title":"Am. J. Nephrol."},{"key":"2021113011105255000_B20","doi-asserted-by":"publisher","first-page":"2072","DOI":"10.2215\/CJN.02840313","article-title":"Treatment of idiopathic FSGS with adrenocorticotropic hormone gel","volume":"8","author":"Hogan","year":"2013","journal-title":"Clin. J. Am. Soc. Nephrol."},{"key":"2021113011105255000_B21","doi-asserted-by":"publisher","first-page":"13","DOI":"10.3389\/fmed.2015.00013","article-title":"A case report of adrenocorticotropic hormone to treat recurrent focal segmental glomerular sclerosis post-transplantation and biomarker monitoring","volume":"2","author":"Anwar","year":"2015","journal-title":"Front. Med."},{"key":"2021113011105255000_B22","doi-asserted-by":"publisher","first-page":"2016","DOI":"10.1542\/peds.2016-2169","article-title":"Acquired Resistance to Corticotropin Therapy in Nephrotic Syndrome: Role of De Novo Neutralizing Antibody","volume":"140","author":"Wang","year":"2017","journal-title":"Pediatrics."},{"key":"2021113011105255000_B23","doi-asserted-by":"publisher","first-page":"1290","DOI":"10.1681\/ASN.2009101025","article-title":"Melanocortin 1 receptor agonists reduce proteinuria","volume":"21","author":"Lindskog","year":"2010","journal-title":"J. Am. Soc. Nephrol."},{"key":"2021113011105255000_B24","doi-asserted-by":"publisher","first-page":"27589","DOI":"10.1038\/srep27589","article-title":"MC1R is dispensable for the proteinuria reducing and glomerular protective effect of melanocortin therapy","volume":"6","author":"Qiao","year":"2016","journal-title":"Sci. Rep."},{"key":"2021113011105255000_B25","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1681\/ASN.2007111205","article-title":"Adriamycin alters glomerular endothelium to induce proteinuria","volume":"20","author":"Jeansson","year":"2009","journal-title":"J. Am. Soc. Nephrol."},{"key":"2021113011105255000_B26","doi-asserted-by":"publisher","first-page":"381","DOI":"10.1111\/cei.12336","article-title":"Alpha-melanocyte stimulating hormone ameliorates disease activity in an induced murine lupus-like model","volume":"177","author":"Botte","year":"2014","journal-title":"Clin. Exp. Immunol."},{"key":"2021113011105255000_B27","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1002\/path.4692","article-title":"The beta isoform of GSK3 mediates podocyte autonomous injury in proteinuric glomerulopathy","volume":"239","author":"Li","year":"2016","journal-title":"J. Pathol."},{"key":"2021113011105255000_B28","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1186\/1471-2369-13-14","article-title":"Acatalasemic mice are mildly susceptible to adriamycin nephropathy and exhibit increased albuminuria and glomerulosclerosis","volume":"13","author":"Takiue","year":"2012","journal-title":"BMC Nephrol."},{"key":"2021113011105255000_B29","doi-asserted-by":"publisher","first-page":"168","DOI":"10.1136\/gutjnl-2013-306043","article-title":"Therapeutic targeting of GSK3beta enhances the Nrf2 antioxidant response and confers hepatic cytoprotection in hepatitis C","volume":"64","author":"Jiang","year":"2015","journal-title":"Gut"},{"key":"2021113011105255000_B30","doi-asserted-by":"publisher","first-page":"799","DOI":"10.1016\/S0002-9440(10)64239-3","article-title":"A new method for large scale isolation of kidney glomeruli from mice","volume":"161","author":"Takemoto","year":"2002","journal-title":"Am. J. Pathol."},{"key":"2021113011105255000_B31","doi-asserted-by":"publisher","first-page":"2289","DOI":"10.1681\/ASN.2015050565","article-title":"Genetic and Pharmacologic Targeting of Glycogen Synthase Kinase 3beta Reinforces the Nrf2 Antioxidant Defense against Podocytopathy","volume":"27","author":"Zhou","year":"2016","journal-title":"J. Am. Soc. Nephrol."},{"key":"2021113011105255000_B32","doi-asserted-by":"publisher","first-page":"2742","DOI":"10.1016\/j.ajpath.2014.06.027","article-title":"Glycogen synthase kinase 3beta dictates podocyte motility and focal adhesion turnover by modulating paxillin activity: implications for the protective effect of low-dose lithium in podocytopathy","volume":"184","author":"Xu","year":"2014","journal-title":"Am. J. Pathol."},{"key":"2021113011105255000_B33","doi-asserted-by":"publisher","first-page":"1342","DOI":"10.1046\/j.1523-1755.2000.00291.x","article-title":"A simple method to detect an albumin permeability factor in the idiopathic nephrotic syndrome","volume":"58","author":"Pegoraro","year":"2000","journal-title":"Kidney Int."},{"key":"2021113011105255000_B34","doi-asserted-by":"publisher","first-page":"299","DOI":"10.2353\/ajpath.2008.070057","article-title":"Epithelial-to-mesenchymal transition is a potential pathway leading to podocyte dysfunction and proteinuria","volume":"172","author":"Li","year":"2008","journal-title":"Am. J. Pathol."},{"key":"2021113011105255000_B35","doi-asserted-by":"publisher","first-page":"635","DOI":"10.1038\/ki.2012.447","article-title":"Adrenocorticotropic hormone ameliorates acute kidney injury by steroidogenic-dependent and -independent mechanisms","volume":"83","author":"Si","year":"2013","journal-title":"Kidney Int."},{"key":"2021113011105255000_B36","doi-asserted-by":"publisher","first-page":"1128","DOI":"10.1038\/ki.2008.380","article-title":"Candesartan suppresses chronic renal inflammation by a novel antioxidant action independent of AT1R blockade","volume":"74","author":"Chen","year":"2008","journal-title":"Kidney Int."},{"key":"2021113011105255000_B37","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1111\/j.1440-1797.2010.01383.x","article-title":"Adriamycin nephropathy: a model of focal segmental glomerulosclerosis","volume":"16","author":"Lee","year":"2011","journal-title":"Nephrology (Carlton, Vic.)."},{"key":"2021113011105255000_B38","doi-asserted-by":"publisher","first-page":"577","DOI":"10.1007\/s11626-009-9232-3","article-title":"Purification and growth of melanocortin 1 receptor (Mc1r)- defective primary murine melanocytes is dependent on stem cell factor (SFC) from keratinocyte-conditioned media","volume":"45","author":"Scott","year":"2009","journal-title":"In vitro Cell. Dev. Biol. Animal"},{"key":"2021113011105255000_B39","doi-asserted-by":"crossref","first-page":"1339","DOI":"10.33594\/000000094","article-title":"Melanocortin-1 Receptor Positively Regulates Human Artery Endothelial Cell Migration","volume":"52","author":"Saporiti","year":"2019","journal-title":"Cell. Physiol. Biochem.: Int. J. Exp. Cell. Physiol. Biochem. Pharmacol."},{"key":"2021113011105255000_B40","doi-asserted-by":"publisher","first-page":"1678","DOI":"10.1161\/ATVBAHA.114.305064","article-title":"Deficiency in Melanocortin 1 Receptor Signaling Predisposes to Vascular Endothelial Dysfunction and Increased Arterial Stiffness in Mice and Humans","volume":"35","author":"Rinne","year":"2015","journal-title":"Arteriosclerosis Thrombosis Vasc. Biol."},{"key":"2021113011105255000_B41","doi-asserted-by":"publisher","first-page":"e87816","DOI":"10.1371\/journal.pone.0087816","article-title":"Effects of melanocortin 1 receptor agonists in experimental nephropathies","volume":"9","author":"Lindskog Jonsson","year":"2014","journal-title":"PLoS ONE"},{"key":"2021113011105255000_B42","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1054\/npep.2000.0778","article-title":"Evidence that alpha-MSH induced grooming is not primarily mediated by any of the cloned melanocortin receptors","volume":"34","author":"Sanchez","year":"2000","journal-title":"Neuropeptides"},{"key":"2021113011105255000_B43","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1016\/S0196-9781(99)00207-7","article-title":"New highly specific agonistic peptides for human melanocortin MC(1) receptor","volume":"21","author":"Szardenings","year":"2000","journal-title":"Peptides"},{"key":"2021113011105255000_B44","doi-asserted-by":"publisher","first-page":"1443","DOI":"10.1038\/eye.2017.74","article-title":"Aqueous humor endothelin-1 and total retinal blood flow in patients with non-proliferative diabetic retinopathy","volume":"31","author":"Khuu","year":"2017","journal-title":"Eye (Lond)"},{"key":"2021113011105255000_B45","doi-asserted-by":"publisher","first-page":"F846","DOI":"10.1152\/ajprenal.00231.2015","article-title":"Melanocortin 1 receptor agonist protects podocytes through catalase and RhoA activation","volume":"310","author":"Elvin","year":"2016","journal-title":"Am. J. Physiol. Renal Physiol."},{"key":"2021113011105255000_B46","doi-asserted-by":"publisher","first-page":"15731","DOI":"10.1038\/s41598-018-34004-7","article-title":"Amplification of the Melanocortin-1 Receptor in Nephrotic Syndrome Identifies a Target for Podocyte Cytoskeleton Stabilization","volume":"8","author":"Bergwall","year":"2018","journal-title":"Sci. Rep."},{"key":"2021113011105255000_B47","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1053\/snep.2003.50012","article-title":"Pathologic classification of focal segmental glomerulosclerosis","volume":"23","author":"D'Agati","year":"2003","journal-title":"Semin. Nephrol."}],"container-title":["Clinical Science"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/portlandpress.com\/clinsci\/article-pdf\/134\/7\/695\/870624\/cs-2020-0016.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/portlandpress.com\/clinsci\/article-pdf\/134\/7\/695\/870624\/cs-2020-0016.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,11,30]],"date-time":"2021-11-30T12:09:44Z","timestamp":1638274184000},"score":1,"resource":{"primary":{"URL":"https:\/\/portlandpress.com\/clinsci\/article\/134\/7\/695\/222355\/Melanocortin-therapy-ameliorates-podocytopathy-and"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,3,30]]},"references-count":47,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2020,4,17]]}},"URL":"https:\/\/doi.org\/10.1042\/cs20200016","relation":{},"ISSN":["0143-5221","1470-8736"],"issn-type":[{"value":"0143-5221","type":"print"},{"value":"1470-8736","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2020,4]]},"published":{"date-parts":[[2020,3,30]]}}}